Reuters
21 Jul 2026, 20:44 UTC · 9w ago
Verdict
Headline takes no side. We score CLDX −0.80 across one claim — strongly bearish.
−0.80strongly bearish
More negative than 86% of ticker scores this week
What the story claims
1 claim · scored −1 bearish … +1 bullish
Celldex Therapeutics is discontinuing the development of its experimental skin disease drug after it failed to meet primary and key secondary goals in a mid-stage study.
More negative than 99% of claims this week
Which stocks this story touches
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More negative than 86% of ticker scores this week
The company is discontinuing an experimental drug after it failed to meet goals in a mid-stage study, leading to a share price drop.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
−13.4%
Price agrees with the score
$30.88 vs $35.66 close before publication (Jul 21) · not market-adjusted
CLDX chart →
